研究者
J-GLOBAL ID：202301005077315292
更新日: 2024年07月10日
大池 直樹
オオイケ ナオキ | OIKE NAOKI
所属機関・部署：
職名：
助教
競争的資金等の研究課題 (1件)：
- 2022 - 2024 軟部肉腫におけるNK細胞療法の開発
論文 (18件)：
-
Osamu Ansai, Ryota Hayashi, Anna Nakamura, Jin Sasaki, Akito Hasegawa, Tokiko Deguchi, Akihiko Yuki, Naoki Oike, Takashi Ariizumi, Masahiro Abe, et al. Deep dermatophytosis caused by Trichophyton rubrum in an elderly patient with CARD9 deficiency: A case report and literature review. The Journal of dermatology. 2024. 51. 2. 294-300
-
Yudai Murayama, Yasushi Kasahara, Nobuhiro Kubo, Chansu Shin, Masaru Imamura, Naoki Oike, Takashi Ariizumi, Akihiko Saitoh, Minori Baba, Tomohiro Miyazaki, et al. NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma. Translational oncology. 2022. 25. 101521-101521
-
Takashi Ariizumi, Hiroyuki Kawashima, Tetsuro Yamagishi, Naoki Oike, Yudai Murayama, Hajime Umezu, Naoto Endo, Akira Ogose. Diagnostic accuracy of fine needle aspiration cytology and core needle biopsy in bone and soft tissue tumor: A comparative study of the image-guided and blindly performed procedure. Annals of diagnostic pathology. 2022. 59. 151936-151936
-
Naoki Oike, Hiroyuki Kawashima, Akira Ogose, Hiroshi Hatano, Takashi Ariizumi, Tetsuro Yamagishi, Yudai Murayama, Hajime Umezu, Chihaya Imai, Masanori Hayashi, et al. Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas. Cancer immunology, immunotherapy : CII. 2021. 70. 12. 3489-3499
-
Yudai Murayama, Hiroyuki Kawashima, Nobuhiro Kubo, Chansu Shin, Yasushi Kasahara, Masaru Imamura, Naoki Oike, Takashi Ariizumi, Akihiko Saitoh, Keichiro Mihara, et al. Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma. Translational oncology. 2021. 14. 12. 101227-101227
もっと見る
学位 (1件)：
受賞 (2件)：
- 2022/06 - 新潟大学医学部学士会 令和四年度有任記念学術奨励賞 脂肪肉腫における腫瘍免疫環境と予後との関連
- 2019/12 - University of Colorado University of Colorado Postdoctoral Association Travelling Award High-throughput drug screening combined with a druggable target CRISPR drop-out screen identifies therapeutic vulnerabilities of BCOR-CCNB3 fusion positive sarcomas
前のページに戻る
